Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Amsterdam, Netherlands
NCT Number: NCT06589427
Four prospective observational studies of ventilation in critically ill patients were harmonized and pooled.
Looking for future studies?
Notify Me16 year–99 year
All sexes
Observational
Amsterdam, Netherlands
The individual data from four observational studies ('Epidemiology of Respiratory Insufficiency in Critical Care study' [ERICC], the 'Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure' [LUNG SAFE], 'PRactice of VENTilation in critically ill patients without ARDS' [PRoVENT], 'PRactice of VENTilation in critically ill patients in Middle-income Countries' [PRoVENT-iMiC]) were harmonized and pooled into a database named 'PRoPERLy II'. This database will be used to address various issues in diverse patient categories.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
ERICC included patients aged 18 years or older that received ventilatory support for at least 24 hours during the first 48 hours of ICU admission at the participating ICUs. ERICC excluded patients with a tracheostomy, patients admitted for routine uncomplicated postoperative care, readmissions and patients with a terminal condition. ERICC enrolled patients during 2-months period.
LUNG SAFE included patients aged 16 years or older that received invasive or noninvasive ventilation. LUNG SAFE excluded patients without informed consent. LUNG SAFE enrolled patients during a 4-week period in the winter months.
PRoVENT included patients aged 18 years or older that received invasive ventilation. PRoVENT excluded patients in whom ventilation was started before the study recruitment week, patients receiving only noninvasive ventilation, and patients that were transferred to the ICU from another hospital under ventilation. PRoVENT enrolled patients during 4-week period.
PRoVENT-iMiC included patients aged 18 years or older that started with invasive ventilation. They excluded patients that received only noninvasive ventilation, patients whose invasive ventilation started before the inclusion phase of the study, and patients transferred from another hospital while under ventilation. PRoVENT-iMiC enrolled patients during 4-week period.
Patients were subjected to invasive ventilation.
Other names: Respiratory support.
Time frame: ICU visit, anticipated average 4 days
Mortality risk based on PaO2/FiO2 or SpO2/FiO2.
Time frame: In the first 4 days of invasive ventilation.
PaO2 values predicted from SpO2 values.
Time frame: In the first 4 days of invasive ventilation.
PaO2/FiO2 predicted from SpO2/FiO2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Prediction of PaO2 from SpO2 Values in Critically Ill Invasively Ventilated Patients - Rationale and Protocol for a Patient-level Analysis of ERICC, LUNG SAFE, PRoVENT and PRoVENT-iMiC (PRoPERLy II)
Acronym: PRoPERLy-II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05968066
Critical Illness, Disease Attributes
Amsterdam, North Holland, Netherlands
View Trial DetailsNCT06592937
Invasive Ventilation
Amsterdam, Netherlands
View Trial DetailsNCT03455413
Elective Surgery, Invasive Ventilation
Oulu, Finland
View Trial DetailsNCT07493785
Agnosia, Chemically-Induced Disorders
Brest, France
View Trial Details